Severe lupus induced by the tumor necrosis factor-alpha inhibitor Anbainuo: a case report.
Adult
Antirheumatic Agents
/ adverse effects
Arthritis, Rheumatoid
/ drug therapy
Female
Humans
Immunoglobulin Fc Fragments
/ therapeutic use
Lupus Erythematosus, Systemic
/ chemically induced
Methotrexate
/ therapeutic use
Receptors, Tumor Necrosis Factor, Type II
/ therapeutic use
Recombinant Fusion Proteins
Tumor Necrosis Factor-alpha
Anbainuo
TNF-α inhibitor
biologic disease-modifying anti-rheumatic drug
case report
drug-induced lupus
rheumatoid arthritis
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
In rare cases, clinical inhibitors of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) can induce symptoms of lupus erythematosus (drug-induced lupus, DIL), but this adverse response usually resolves rapidly upon drug withdrawal. We report the case of a 25-year-old Asian woman with rheumatoid arthritis exhibiting severe prolonged DIL even after the termination of TNF-α inhibitor treatment. The patient had been treated intermittently using Traditional Chinese Medicine for 11 years, but this therapy failed to effectively control her clinical symptoms. Subsequently, methotrexate and hydroxychloroquine were prescribed, but a reduced white blood cell count was detected. Finally, the TNF-α inhibitor Anbainuo was prescribed. However, after 2 months of treatment, the patient exhibited elevated serum creatinine, anti-double-stranded DNA (+++), anti-nuclear antibody (1:1000), and urine protein (+++) accompanied by buccal erythema, hair loss, and hand shaking, consistent with Anbainuo-induced lupus, lupus nephritis, and lupus encephalopathy. Moreover, her serum creatinine level remained high after Anbainuo withdrawal and prolonged steroid and immunosuppressive therapy. Careful and sustained monitoring for adverse reactions to Anbainuo (and other TNF-α inhibitors) is recommended.
Identifiants
pubmed: 34139868
doi: 10.1177/03000605211022510
pmc: PMC8216383
doi:
Substances chimiques
Anbainuo protein, human
0
Antirheumatic Agents
0
Immunoglobulin Fc Fragments
0
Receptors, Tumor Necrosis Factor, Type II
0
Recombinant Fusion Proteins
0
Tumor Necrosis Factor-alpha
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3000605211022510Références
Arthritis Res. 2002;4 Suppl 3:S265-72
pubmed: 12110146
Autoimmun Rev. 2018 Sep;17(9):912-918
pubmed: 30005854
Rheumatology (Oxford). 2012 Apr;51(4):721-9
pubmed: 22179737
Semin Arthritis Rheum. 2008 Jun;37(6):381-7
pubmed: 17977585
Hosp Pract (Off Ed). 1993 Aug 15;28(8):14
pubmed: 8340429
Pol Arch Med Wewn. 2006 Oct;116(4):980-7
pubmed: 18416301
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
Headache. 2013 Nov-Dec;53(10):1541-7
pubmed: 24266334
Lupus. 2014 May;23(6):545-53
pubmed: 24557776
Medicine (Baltimore). 2007 Jul;86(4):242-251
pubmed: 17632266
Curr Opin Rheumatol. 2018 Sep;30(5):490-497
pubmed: 29870500
Autoimmun Rev. 2013 May;12(7):703-8
pubmed: 23207283
Autoimmun Rev. 2010 Jan;9(3):188-93
pubmed: 19854301
Rev Bras Reumatol. 2013 Aug;53(4):358-64
pubmed: 24217668
Postepy Hig Med Dosw (Online). 2007 Aug 28;61:478-84
pubmed: 17786135
Med Clin (Barc). 2010 Jun 19;135(3):124-9
pubmed: 19576598